GlassScriptPhysician profile
James Robert Hoppe
NPI 1174587661
$6,369.76
in general payments reported to CMS, 2019-2025
30 companies · $815 in 2025
The $815 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $1,020 · 2021: $1,017 · 2022: $791 · 2023: $688 · 2024: $845 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313 · Education: $35.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.89 |
| Education | $35.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,774.64 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $767.77 | 2019-2025 | |
| Lilly USA, LLC | $534.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $497.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $366.32 | 2023-2025 | |
| Exact Sciences Corporation | $312.82 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $305.01 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $299.01 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $224.54 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $175.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.57 | 2019-2022 | |
| Hologic Sales and Service, LLC | $136.43 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $116.03 | 2019-2025 | |
| Avion Pharmaceuticals | $80.21 | 2019-2022 | |
| Amarin Pharma, INC. | $72.03 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.66 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Antares Pharma, INC. | $63.27 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.37 | 2019 | |
| Myovant Sciences INC. | $46.01 | 2022 | |
| Impel Pharmaceuticals INC. | $45.72 | 2023 | Trudhesa |
| Glaxosmithkline, LLC. | $41.57 | 2019-2024 | Arexvy |
| Phadia US INC. | $35.38 | 2022-2024 | Immunocap |
| Corcept Therapeutics | $33.85 | 2025 | Korlym |
| Agile Therapeutics, INC. | $28.72 | 2022 | |
| Clarus Therapeutics INC. | $19.71 | 2021 | |
| Lupin INC. | $14.81 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.35 | 2021 | |
| Horizon Therapeutics Plc | $13.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hoppe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.